9920 Belward Campus Drive, Rockville, MD 20850
Phone: (240) 268-2000 Website: www.novavax.com
Investor & Media Relations: ir@novavax.com
Employment Opportunities: hr@novavax.com
Our Mission
Novavax, Inc. (Nasdaq: NVAX), a clinical-stage
biopharmaceutical company, employs its cuttingedge technology to create next-generation
vaccines to prevent serious infectious diseases,
such as pandemic and seasonal flu and respiratory
syncytial virus (RSV). The company’s proprietary
virus-like particle (VLP) technology and single-use
bioprocessing system enable rapid vaccine
development and production where and when
needed, worldwide. For more information about
Novavax, please visit www.novavax.com.
Proprietary Technology
VLPs mimic the external structure of viruses but
lack the live genetic material that causes viral
replication and infection. VLPs can be designed
quickly to match individual viral strains and be
produced efficiently using portable cell-culture
technology. Novavax VLP-based vaccine
candidates are produced more rapidly than eggbased vaccines using proprietary, portable,
recombinant cell-culture technology.
Highlights
May 2011
Novavax Named Biotechnology Firm of the
Year by Tech Council of Maryland
February 2011
NOVAVAX Awarded HHS-BARDA Contract
Valued Up to $179 Million to Develop
Pandemic and Seasonal Influenza Vaccines
January 2011
Launches Phase I Clinical Trial for RSV
December 2010
Novavax and UM School of Med Report that
RSV Vaccine Candidate Completely Protects
Mice From RSV Replication in Lungs in
Preclinical Study
August 2010
Endorsed New U.S. Initiatives to Develop
Medical Countermeasures
Acknowledged by the President’s Council of
Advisors on Science & Technology (PCAST) in
the “Report to the President on Reengineering
the Influenza Vaccine Production Enterprise to
Meet the Challenges of Pandemic Influenza”
Shared Positive Results from Preclinical Safety
Study of Novavax Respiratory Syncytial Virus
(RSV) Vaccine Candidate
Collaborations & Partnerships
 HHS BARDA – contract to develop pandemic and
seasonal influenza vaccine
 Cadila Pharmaceuticals (CPL Biologicals) –
joint venture for development and production
of VLP vaccines in India
 Novavax Licenses Recombinant VLP Influenza
Vaccine to LG Life Sciences for South Korea and
Other Countries
July 2010
Key U.S. Patent Issued to Novavax for
Influenza Virus-Like Particle Vaccines
Nasdaq Stock Symbol
52-week range
Stock price (7/1/11)
Employees (7/1/11)
Incorporated
IPO
NVAX
$1.92-3.17
$1.97
110
1987
1995
Management Team
Stanley C. Erck, M.B.A.
President and CEO
Gregory Glenn, M.D.
Senior Vice President, Chief Medical Officer
John Trizzino, M.B.A.
Senior Vice President, Business Development
Timothy Hahn, Ph.D.
Senior Vice President, Manufacturing
Fred Driscoll
Vice President, Chief Financial Officer and
Treasurer
Louis Fries, III, M.D.
Vice President, Clinical Affairs
Jane Halpern, Ph.D.
Vice President, Regulatory Affairs
Gale Smith, Ph.D.
Vice President, Vaccine Development
Denise G. Courbron, M.S., PMP
Executive Director, Global Program Management
John Herrmann III, J.D.
Executive Director, Legal Affairs and Corporate
Secretary
Recombinant cell verses traditional egg-based manufacturing
Novavax’s single-use bioprocessing system has significant advantages
over the traditional egg-based method. Less space is needed; it takes
one 1,000 liter stir tank compared to one million eggs to produce one
million doses of vaccine. The use of disposables makes it efficient and
highly cost effective. Furthermore, Novavax can produce reliable and
effective flu vaccine in about half the time it takes for the traditional
egg-based method. Novavax stands ready to partner with
governments to quickly respond when the next influenza pandemic
strikes.
Jill Hoyt, SPHR, CCP
Executive Director, Human Resources &
Administration
Board of Directors
James Young, Ph.D.
Chairman
Former President R & D, MedImmune, Inc.
Richard Douglas, Ph.D.
Senior Vice President, Corporate Development,
Genzyme Corporation
Gary C. Evans
Chairman and Chief Executive Officer and
founder of GreenHunter Energy, Inc., Owner and
co-founder, Wind Hunter, LLC, Retired Chairman,
President and Chief Executive,
Magnum Hunter Resources, Inc.
John O. Marsh, Jr.
Distinguished Professor of Law, George Mason
University, Former Secretary of the Army and
U.S. Congressional Representative
Michael A. McManus, Jr.
President, Chief Executive Officer and Director,
Misonix, Inc.
Dr. Rajiv I. Modi
Managing Director, Cadila Pharmaceuticals
Pending Milestones
 Announcement of new vaccine candidate target in 2011.
 Execute regional deal licensing agreement.
 Seasonal Flu – Head to head Phase II data in older adults.
 RSV – Top-Line Phase I data.
Stanley C. Erck, M.B.A.
President and Chief Executive Officer,
Novavax, Inc.